FMP
NASDAQ
8.3 USD
0.14 (1.69%)
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Healthcare
Biotechnology
https://www.relaytx.com
NASDAQ
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology re...
0001812364
US75943R1023
75943R102
399 Binney Street
617 370 8837
US
323
Jul 16, 2020
0001812364
NASDAQ
Biotechnology
Healthcare
75943R102
US75943R1023
US
8.3
1.66
1.1M
1.09B
-
5.95-19.23
-0
-
-
-
-
-2.97
-
https://www.relaytx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.